|
|
|
| Effect of collaborative follow-up management for prostate-specific antigen gray zone among individuals undergoing physical examinations |
| SHAO Yinyan, ZHOU Heran, DENG Xueyu
|
| Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310007, China |
|
|
|
|
Abstract Objective To evaluate the intervention effect of collaborative follow-up management by urological specialists and health management center coordinators on individuals with prostate-specific antigen (PSA) in the gray zone undergoing physical examinations. Methods Participants who underwent physical examinations at the Health Management Center of Hangzhou Hospital of Traditional Chinese Medicine from 2022 to 2024 and had initial serum PSA levels of 4.0-10.0 ng/mL were enrolled as study subjects. Examinees with PSA in the gray zone identified from January 2022 to December 2023 were assigned to the control group and received routine management, while those identified from January to December 2024 were assigned to the intervention group and received collaborative follow-up management. Basic information, follow-up data, re-examination records and treatment outcomes were collected through the Health Management Center's examination information system, laboratory system, and follow-up registration records of the Hangzhou Hospital of Traditional Chinese Medicine. The prostate cancer-related knowledge was assessed using the Prostate Cancer Awareness Questionnaire. The follow-up accessibility, re-examination adherence, and pathological diagnosis rate of prostate cancer were compared between the two groups. The differences in prostate cancer knowledge scores between the two groups before and after intervention were compared using repeated-measures analysis of variance. Results There were 2 188 participants in the control group and 1 294 participants in the intervention group. No significant differences were found between the two groups in marital status, smoking, hypertension, diabetes mellitus, benign prostatic hyperplasia, chronic prostatitis, family history of prostate cancer and initial PSA level (all P>0.05). The follow-up accessibility and re-examination adherence in the intervention group were higher than in the control group (96.68% vs. 88.03%, 91.19% vs. 37.52%, both P<0.05). The acquisition rate of traceable treatment outcome records and pathological diagnosis rate of prostate cancer were higher than in the control group (89.88% vs. 35.37%, 12.21% vs. 9.04%, both P<0.05). Repeated-measures analysis of variance revealed a significant interaction effect between group and time for prostate cancer knowledge scores (P<0.05). The increase in scores from baseline to post-intervention was 4.53 points in the intervention group, which was greater than the 2.05 points observed in the control group. Conclusion Collaborative follow-up management can improve re-examination adherence and the completeness of treatment outcome records among examinees with PSA in the gray zone, enhance prostate cancer-related knowledge, and facilitate early detection of prostate cancer.
|
|
Received: 18 December 2025
Revised: 05 May 2026
Published: 22 June 2026
|
|
|
|
|
|
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究,2021,48(1):98-102.
[3] 邹浩然,范医东,吕仁广.超声引导下经会阴与经直肠途径前列腺穿刺的临床应用效果对比[J].山东第一医科大学(山东省医学科学院)学报,2022,43(3):205-208.
[4] 杜丽娜,张遵浩,管梦娇,等.新型FP-Growth模型在预测PSA为4~10 ng/mL的前列腺癌中应用研究[J].中国男科学杂志,2025,39(2):45-51.
[5] 赫捷,陈万青,李霓,等.中国前列腺癌筛查与早诊早治指南(2022,北京)[J].中华肿瘤杂志,2022,44(1):29-53.
[6] 中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组.前列腺癌筛查中国专家共识(2021年版)[J].中国癌症杂志,2021,31(5):435-440.
[7] WEI J T,BAROCAS D,CARLSSON S,et al.Early detection of prostate cancer:AUA/SUO guideline part I:prostate cancer screening:erratum[J/OL].J Urol,2025,214(1)[2026-05-05].http://doi.org/10.1097/JU.0000000000004546.
[8] 陶逸然,余佳倩,蒋聿瑛,等.基于PSA的前列腺癌筛查临床特征与分层干预研究:单中心经验[J].临床泌尿外科杂志,2025,40(6):529-534.
[9] 罗志强,黄建文,曹乃龙,等.基于PI-RADS v2评分在PSA 4~10 ng/mL患者前列腺癌预测模型的构建及验证[J].临床泌尿外科杂志,2022,37(2):109-113,118.
[10] 毕新刚. 前列腺癌PSA筛查国内外研究进展[J].中国现代医药杂志,2023,25(12):1-8.
[11] 陈可欣,陈万青,黄育北,等.常见恶性肿瘤联合筛查专家共识(2025版)[J].中国肿瘤临床,2025,52(14):703-726.
[12] 秦晓健,顾成元,黄永强,等.基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究[J].中国卫生经济,2021,40(6):9-13. |
|
|
|
